Odronextamab Monotherapy vs Standard of Care Therapy for Follicular Lymphoma: OLYMPIA-1 Trial
Elizabeth Brem, MD, University of California, Irvine, discusses safety and preliminary efficacy results for odronextamab monotherapy in patients with high-risk Grade 1–3a follicular lymphoma (FL) from the safety lead-in part of the phase 3 OLYMPIA-1 trial.
These findings were presented at the 66th ASH Annual Meeting in San Diego, California.
Transcript:
I'm Liz Brem, I am an associate clinical professor at UC Irvine and I'm here at ASH 2024 in San Diego.
I presented a poster on a study called OLYMPIA-1, which is ultimately going to be a randomized phase 3 study of odronextamab, which is a CD20-CD3 bispecific antibody versus the investigator’s choice of chemoimmunotherapy.
In this abstract, we're presenting a safety lead-in of 12 evaluable patients, and we wanted to look at the tolerability and the safety before we moved into the randomized phase III component. The overall response rate was 100%, which we're really encouraged about. We'll see how that plays out in terms of progression-free survival over time.
In terms of safety, we did see some cytokine release syndrome which is not a surprise. But it was all grade 1, so hopefully patients were just hanging out at home and taking some steroids.
We also did see some grade 3 infections, however they weren't to the point where anybody had to stop therapy, so we'll see how that compares in the long run compared to the chemoimmunotherapy arm when we do the randomized component.
Source:
Brem E, Jurczak W, Belada D, et al. Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study. Presented at the 66th ASH Annual Meeting & Exposition; December 7-10, 2024; San Diego, California. Abstract 4411.
